<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337779</url>
  </required_header>
  <id_info>
    <org_study_id>GA/9016 (FORTE)</org_study_id>
    <nct_id>NCT00337779</nct_id>
  </id_info>
  <brief_title>Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).</brief_title>
  <official_title>A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the
      treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA),
      a marketed medication, approved for the treatment of R-R MS. GA is an immunomodulating drug
      that has anti inflammatory and neuroprotective properties. The study treatment duration is 12
      months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).</measure>
    <time_frame>12 months</time_frame>
    <description>A confirmed relapse is defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities. This change in clinical state must last at least 48 hours and be immediately preceded by an improving neurological state of at least thirty (30) days from onset of previous relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of New T2 Lesions at Month 12 as Compared to the Baseline Scan.</measure>
    <time_frame>12 months</time_frame>
    <description>The analysis of this endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression including the number of T1 Gd-enhancing lesions at baseline, the volume of T2 lesions at baseline and (pooled) center as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cumulative Number of T1-Gd Enhancing Lesions at Months 3, 6, 9 and 12 (in the Frequent MRI Cohort-described Below).</measure>
    <time_frame>12 months</time_frame>
    <description>The Frequent MRI Cohort was a subset of subjects consisting of 234 subjects, for whom MRI scans were performed at months 0 (baseline), 1, 2, 3, 6, 9 and 12. Analysis of the endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression with an &quot;offset&quot; variable employing the log of the porportion of the number of available post-baseline scans to adjust for missing MRI scans (if any) and including the number of T1 Gd-enhancing lesions at baseline and (pooled) center as covariates.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1155</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>glatiramer acetate 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>glatiramer acetate 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate (GA) 40 mg</intervention_name>
    <description>Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months</description>
    <arm_group_label>glatiramer acetate 40 mg</arm_group_label>
    <other_name>Copaxone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glatiramer acetate 20 mg</intervention_name>
    <description>Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months</description>
    <arm_group_label>glatiramer acetate 20 mg</arm_group_label>
    <other_name>Copaxone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of confirmed and documented MS defined by the Revised McDonald criteria.

          2. Subjects must be of the relapsing-remitting (R-R) type.

          3. Subject has experienced prior to screening at least one documented relapse in 12
             months or at least 2 documented relapses in the 24 months or one documented relapse
             between 12 - 24 months with at least 1 documented T1-Gd enhancing lesion in the MRI
             performed 12 months prior screening.

          4. Disease duration for at least 6 months.

          5. Ambulatory with converted Kurtzke EDSS score of 0 - 5.

          6. Relapse free and stable neurological condition at least for 30 days prior screening.

          7. Age - 18-55 (inclusive)

        Exclusion Criteria:

          1. Previous use of Copaxone (glatiramer acetate)

          2. Treatment with corticosteroids within 30 days prior screening or between screening and
             baseline.

          3. Chronic corticosteroids treatment - more than 30 consecutive days.

          4. Subject with any clinically significant or unstable medical condition.

          5. Subjects participating in any other clinical trial (within 12 weeks prior to screening
             and thereafter).

          6. Known history of sensitivity to Gadolinium and inability to successfully undergo MRI
             scanning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Duksin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Teva Pharmaceutical Industries, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giancarlo Comi, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Scientifico Fondazione Centro S. Raffaele</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2006</study_first_posted>
  <results_first_submitted>January 18, 2010</results_first_submitted>
  <results_first_submitted_qc>April 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2010</results_first_posted>
  <last_update_submitted>October 6, 2011</last_update_submitted>
  <last_update_submitted_qc>October 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted according to laws, regulations and administrative provisions related to implementation of Good Clinical Practice as applicable by legislation directives and Standard Operating Procedures. Subjects entered study after being informed and given time to contemplate consent. Enrollment began September 2006 and completed May 2007</recruitment_details>
      <pre_assignment_details>All subjects underwent evaluations including vital signs (blood pressure, pulse, and temperature,) adverse events, concomitant medications and neurological evaluation prior to study entry.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glatiramer Acetate 20 mg</title>
        </group>
        <group group_id="P2">
          <title>Glatiramer Acetate 40 mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="586"/>
                <participants group_id="P2" count="569"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="534"/>
                <participants group_id="P2" count="490"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glatiramer Acetate 20 mg</title>
        </group>
        <group group_id="B2">
          <title>Glatiramer Acetate 40 mg</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="586"/>
            <count group_id="B2" value="569"/>
            <count group_id="B3" value="1155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="586"/>
                    <measurement group_id="B2" value="569"/>
                    <measurement group_id="B3" value="1155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="9.0"/>
                    <measurement group_id="B2" value="36.3" spread="9.0"/>
                    <measurement group_id="B3" value="36.3" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="407"/>
                    <measurement group_id="B3" value="828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).</title>
        <description>A confirmed relapse is defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities. This change in clinical state must last at least 48 hours and be immediately preceded by an improving neurological state of at least thirty (30) days from onset of previous relapse.</description>
        <time_frame>12 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate 20 mg</title>
          </group>
          <group group_id="O2">
            <title>Glatiramer Acetate 40 mg</title>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).</title>
          <description>A confirmed relapse is defined as the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities. This change in clinical state must last at least 48 hours and be immediately preceded by an improving neurological state of at least thirty (30) days from onset of previous relapse.</description>
          <population>ITT</population>
          <units>Number of relapses per patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="569"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.58"/>
                    <measurement group_id="O2" value="0.27" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4859</p_value>
            <method>Regression, Poisson</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.0732</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8799</ci_lower_limit>
            <ci_upper_limit>1.3090</ci_upper_limit>
            <estimate_desc>980 subjects randomized into two arms provide approximately 90% power to detect significant difference between groups of 30% or more in rate of confirmed relapses.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of New T2 Lesions at Month 12 as Compared to the Baseline Scan.</title>
        <description>The analysis of this endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression including the number of T1 Gd-enhancing lesions at baseline, the volume of T2 lesions at baseline and (pooled) center as covariates.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate 20 mg</title>
          </group>
          <group group_id="O2">
            <title>Glatiramer Acetate 40 mg</title>
          </group>
        </group_list>
        <measure>
          <title>The Number of New T2 Lesions at Month 12 as Compared to the Baseline Scan.</title>
          <description>The analysis of this endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression including the number of T1 Gd-enhancing lesions at baseline, the volume of T2 lesions at baseline and (pooled) center as covariates.</description>
          <units>T2 Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="586"/>
                <count group_id="O2" value="569"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="6.57"/>
                    <measurement group_id="O2" value="2.72" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cumulative Number of T1-Gd Enhancing Lesions at Months 3, 6, 9 and 12 (in the Frequent MRI Cohort-described Below).</title>
        <description>The Frequent MRI Cohort was a subset of subjects consisting of 234 subjects, for whom MRI scans were performed at months 0 (baseline), 1, 2, 3, 6, 9 and 12. Analysis of the endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression with an &quot;offset&quot; variable employing the log of the porportion of the number of available post-baseline scans to adjust for missing MRI scans (if any) and including the number of T1 Gd-enhancing lesions at baseline and (pooled) center as covariates.</description>
        <time_frame>12 months</time_frame>
        <population>Frequent MRI cohort</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate 20 mg</title>
          </group>
          <group group_id="O2">
            <title>Glatiramer Acetate 40 mg</title>
          </group>
        </group_list>
        <measure>
          <title>The Cumulative Number of T1-Gd Enhancing Lesions at Months 3, 6, 9 and 12 (in the Frequent MRI Cohort-described Below).</title>
          <description>The Frequent MRI Cohort was a subset of subjects consisting of 234 subjects, for whom MRI scans were performed at months 0 (baseline), 1, 2, 3, 6, 9 and 12. Analysis of the endpoint was based on the outcome of a contrast derived from a baseline-adjusted Negative Binomial Regression with an &quot;offset&quot; variable employing the log of the porportion of the number of available post-baseline scans to adjust for missing MRI scans (if any) and including the number of T1 Gd-enhancing lesions at baseline and (pooled) center as covariates.</description>
          <population>Frequent MRI cohort</population>
          <units>T1 Enhancing Lesions</units>
          <param>Log Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="6.58"/>
                    <measurement group_id="O2" value="3.49" spread="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glatiramer Acetate 20 mg</title>
        </group>
        <group group_id="E2">
          <title>Glatiramer Acetate 40 mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Swollen Tongue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Chillls</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Palatal Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Biliary Dyskinesai</sub_title>
                <description>Gallbladder Disorder</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Anaphylactic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Hypersensititvity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <description>Fungal Infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complicated Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Crush Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram Coronary</sub_title>
                <description>Diagnostic Procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Troponin Increased</sub_title>
                <description>Laboratory Abnormal</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <description>Arthropathy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of Breast</sub_title>
                <description>Breast Neoplasm</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Metastases to Lymph Nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Facial Palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Radicular Syndrome</sub_title>
                <description>Neuropathy Peripheral</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <description>Syncope</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic Attack</sub_title>
                <description>Agitation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Neophrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Coronary Arterial Stent Insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Laparoscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Malignant Breast Lump Removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Oophorectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Spinal Laminectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Varicose Vein Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="499" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="490" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="586"/>
                <counts group_id="E2" events="45" subjects_affected="33" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Asthenia</description>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="586"/>
                <counts group_id="E2" events="44" subjects_affected="41" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="43" subjects_affected="32" subjects_at_risk="586"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Erythema</sub_title>
                <counts group_id="E1" events="200" subjects_affected="183" subjects_at_risk="586"/>
                <counts group_id="E2" events="231" subjects_affected="196" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising</sub_title>
                <counts group_id="E1" events="35" subjects_affected="31" subjects_at_risk="586"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Site Irritation</sub_title>
                <description>Injection Site Inflamation</description>
                <counts group_id="E1" events="62" subjects_affected="57" subjects_at_risk="586"/>
                <counts group_id="E2" events="47" subjects_affected="42" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <description>Injection Site Mass</description>
                <counts group_id="E1" events="47" subjects_affected="46" subjects_at_risk="586"/>
                <counts group_id="E2" events="62" subjects_affected="54" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Site Mass</sub_title>
                <counts group_id="E1" events="55" subjects_affected="53" subjects_at_risk="586"/>
                <counts group_id="E2" events="70" subjects_affected="63" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <description>Injection Site Oedema</description>
                <counts group_id="E1" events="49" subjects_affected="47" subjects_at_risk="586"/>
                <counts group_id="E2" events="58" subjects_affected="55" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="123" subjects_affected="109" subjects_at_risk="586"/>
                <counts group_id="E2" events="112" subjects_affected="99" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" events="95" subjects_affected="90" subjects_at_risk="586"/>
                <counts group_id="E2" events="99" subjects_affected="93" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="586"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="65" subjects_affected="49" subjects_at_risk="586"/>
                <counts group_id="E2" events="68" subjects_affected="54" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Pharyngitis</description>
                <counts group_id="E1" events="102" subjects_affected="78" subjects_at_risk="586"/>
                <counts group_id="E2" events="95" subjects_affected="74" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="50" subjects_affected="43" subjects_at_risk="586"/>
                <counts group_id="E2" events="38" subjects_affected="30" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="586"/>
                <counts group_id="E2" events="39" subjects_affected="36" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="115" subjects_affected="63" subjects_at_risk="586"/>
                <counts group_id="E2" events="113" subjects_affected="68" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="586"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="569"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="45" subjects_affected="30" subjects_at_risk="586"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="67" subjects_affected="44" subjects_at_risk="586"/>
                <counts group_id="E2" events="79" subjects_affected="54" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <description>Vasodilatation</description>
                <counts group_id="E1" events="42" subjects_affected="26" subjects_at_risk="586"/>
                <counts group_id="E2" events="49" subjects_affected="36" subjects_at_risk="569"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor’s review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor’s designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chen Duksin, MD</name_or_title>
      <organization>Teva Pharmaceutical Industries, Ltd.</organization>
      <phone>972-9-863-4642</phone>
      <email>chen.duksin@teva.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

